Scholarlink

<p>Neoadjuvant pembrolizumab plus chemotherapy improves outcomes in early triple-negative breast cancer, but real-world evidence in patients with pathogenic BRCA1/2 variants remains limited. We analyzed 726 consecutively treated patients from the multicenter Neo-Real/GBECAM-0123 cohort who received at least one cycle of neoadjuvant pembrolizumab plus chemotherapy and underwent surgery. Patients with pathogenic BRCA1/2 variants (<i>mBRCA)</i> were identified in 105 of 600 tested patients (17.5%), corresponding to 14.5% of the overall cohort. Among m<i>BRCA</i> carriers, 82 (78.1%) had <i>BRCA1</i> variants, 22 (21.0%) had <i>BRCA2</i> variants, and in 1 patient (0.1%) the <i>BRCA</i> subtype was not specified. The comparator group comprised 621 patients with wild-type or unknown <i>BRCA</i> status (wt/unknown <i>BRCA</i>). Pathologic complete response was higher in the <i>mBRCA</i> group than in the wt/unknown <i>BRCA</i> group (74.0% vs 61.7%). With a median follow-up of 22 months, event-free and overall survival were favorable in both groups, with a non-significant trend toward improved event-free survival in the m<i>BRCA</i> group, particularly among patients with residual disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohort

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月2日

查看全文
  • Monique Celeste Tavares,
  • Flávia C. Balint,
  • Romualdo Barroso-Sousa,
  • Laura Testa,
  • Pablo Mandó,
  • Natália C. Nunes,
  • Sergio Alejandro Mazzotta,
  • Micaela Rigesti,
  • Isadora. M. Sousa,
  • Matheus O. Andrade,
  • Mariana Gouveia,
  • Fernanda Madasi,
  • José Bines,
  • Rafael D. P. Ferreira,
  • Daniela D. Rosa,
  • Candice L. Santos,
  • Mariana R. Monteiro,
  • Zenaide S. Souza,
  • Daniele Assad-Suzuki,
  • Carlos H. dos Anjos,
  • Débora M. Gagliato,
  • Ana Maria U. Gomes,
  • Bruna M. Zucchetti,
  • Anezka Ferrari,
  • Mayana L. Brito,
  • Maria Marcela F. Monteiro,
  • Gilmara Resende,
  • Noele J. B. Gomes,
  • Maria Victoria Costanzo,
  • Solange Moraes Sanches,
  • Vladmir C. Lima,
  • Jose Claudio Casali Rocha,
  • Elizabeth Santana dos Santos,
  • Fabiana B. Makdissi,
  • Paulo M. Hoff,
  • Maria del Pilar Estevez-Diz,
  • Renata Colombo Bonadio

摘要

Neoadjuvant pembrolizumab plus chemotherapy improves outcomes in early triple-negative breast cancer, but real-world evidence in patients with pathogenic BRCA1/2 variants remains limited. We analyzed 726 consecutively treated patients from the multicenter Neo-Real/GBECAM-0123 cohort who received at least one cycle of neoadjuvant pembrolizumab plus chemotherapy and underwent surgery. Patients with pathogenic BRCA1/2 variants (mBRCA) were identified in 105 of 600 tested patients (17.5%), corresponding to 14.5% of the overall cohort. Among mBRCA carriers, 82 (78.1%) had BRCA1 variants, 22 (21.0%) had BRCA2 variants, and in 1 patient (0.1%) the BRCA subtype was not specified. The comparator group comprised 621 patients with wild-type or unknown BRCA status (wt/unknown BRCA). Pathologic complete response was higher in the mBRCA group than in the wt/unknown BRCA group (74.0% vs 61.7%). With a median follow-up of 22 months, event-free and overall survival were favorable in both groups, with a non-significant trend toward improved event-free survival in the mBRCA group, particularly among patients with residual disease.